Find therapies in clinical trials near you

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

Study of the effect of empagliflozin on protein levels in the urine for patients with type 2 diabetes and kidney disease.

Study of the effect of empagliflozin on protein levels in the urine for patients with type 2 diabetes and kidney disease.

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

A study testing the reduction of heart failure drug combination in patients with heart failure in remission

A study testing the reduction of heart failure drug combination in patients with heart failure in remission

Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

Study of empagliflozin compared to placebo in patients with acute decompensated heart failure who are already taking SGLT2 inhibitors

Study of empagliflozin compared to placebo in patients with acute decompensated heart failure who are already taking SGLT2 inhibitors

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Patients Hospitalized with Heart Failure